Skip to main content

Advertisement

Table 4 Characteristics and medical costs of patients with 12 month-follow-up period pre- and post-BT initiation

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

  Total BT-naïve
ADL IFX UST Sub total ADL IFX UST Subtotal
Number of patients 18 20 37 77 14 19 30 64
Average Age 47.7 46.5 46.2 46.8 49.6 47.3 46.3 47.5
%Female 11.1% 20.0% 16.2% 15.6% 14.3% 21.1% 20.0% 18.8%
Cost (pre) ¥760 ¥950 ¥900 ¥886 ¥365 ¥916 ¥603 ¥641
In 1000 JPY unit IP ¥18 ¥343 ¥254 ¥235 ¥0 ¥361 ¥162 ¥188
OP ¥513 ¥301 ¥425 ¥405 ¥133 ¥261 ¥216 ¥210
RX ¥229 ¥306 ¥221 ¥246 ¥232 ¥294 ¥225 ¥244
Cost increase ¥1538 ¥2429 ¥1865 ¥1907 ¥1853 ¥2494 ¥2221 ¥2187
In 1000 JPY unit IP ¥95 ¥601 - ¥37 ¥156 ¥146 ¥633 ¥21 ¥228
OP ¥1077 ¥1958 ¥2011 ¥1754 ¥1379 ¥1974 ¥2296 ¥1965
RX ¥366 - ¥130 - ¥109 - ¥2 ¥328 - ¥113 - ¥96 - ¥5
  1. ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs